Certara (Certara) Interest Expense : $-22.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Certara Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Certara's interest expense for the three months ended in Dec. 2023 was $ -5.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Certara's Operating Income for the three months ended in Dec. 2023 was $ -8.5 Mil. Certara's Interest Expense for the three months ended in Dec. 2023 was $ -5.9 Mil. Certara did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Certara Interest Expense Historical Data

The historical data trend for Certara's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara Interest Expense Chart

Certara Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-28.00

-25.30

-16.84

-17.77

-22.92

Certara Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial														-5.45	-5.48	-5.67	-5.90	-5.87

Certara Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.9 Mil.

Certara (NAS:CERT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Certara's Interest Expense for the three months ended in Dec. 2023 was $-5.9 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-8.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $295.2 Mil.

Certara's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Certara did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Certara (Certara) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Executives

Richard M. Traynor	officer: See Remarks	1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen	officer: President, Software	10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy	director	C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith	officer: PRESIDENT, INTEGRATED DRUG DEV	C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher	officer: CHIEF FINANCIAL OFFICER	BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p.	10 percent owner	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight	director	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine	director	2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905